Last reviewed 2026-05-27 · How we verify

Taiglididine

The First People's Hospital of Lianyungang · Phase 1 active Small molecule ✓ Verified May 2026

Taiglididine is a Small molecule drug developed by The First People's Hospital of Lianyungang. It is currently in Phase 1 development.

Taiglididine is a medication being studied for its effectiveness in suppressing the laryngeal mask insertion response in elderly patients undergoing urological surgery. It is being investigated in a clinical trial (NCT07096115) to determine its 90% effective dose for this purpose.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Taiglididine
Sponsor	The First People's Hospital of Lianyungang
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Taiglididine CI brief — competitive landscape report
Taiglididine updates RSS · CI watch RSS
The First People's Hospital of Lianyungang portfolio CI

Frequently asked questions about Taiglididine

What is Taiglididine?

Taiglididine is a Small molecule drug developed by The First People's Hospital of Lianyungang.

Who makes Taiglididine?

Taiglididine is developed by The First People's Hospital of Lianyungang (see full The First People's Hospital of Lianyungang pipeline at /company/the-first-people-s-hospital-of-lianyungang).

What development phase is Taiglididine in?

Taiglididine is in Phase 1.

Manufacturer: The First People's Hospital of Lianyungang — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing